Journal article
Clinical utility of Aspergillus galactomannan and PCR in bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in patients with haematological malignancies
SC Heng, SCA Chen, CO Morrissey, K Thursky, RL Manser, HD De Silva, CL Halliday, JF Seymour, RL Nation, DCM Kong, MA Slavin
Diagnostic Microbiology and Infectious Disease | ELSEVIER SCIENCE INC | Published : 2014
Abstract
Interpretation of Aspergillus galactomannan (GM) and PCR results in bronchoalveolar lavage (BAL) fluid for the diagnosis of invasive pulmonary aspergillosis (IPA) in patients with haematological malignancies requires clarification. A total of 116 patients underwent BAL for investigation of new lung infiltrates: 40% were neutropenic, 68% and 36% were receiving mould-active antifungal agents and β-lactam antibiotics. The diagnosis of proven IPA (n. = 3), probable IPA (n. = 15), and possible invasive fungal disease (IFD, n. = 50) was made without inclusion of GM results. BAL GM (at cut-off of 0.8) had lower diagnostic sensitivity for IPA than PCR (61% versus 78%) but higher specificity (93% ver..
View full abstractGrants
Funding Acknowledgements
MS and SCAC have sat on advisory boards for and received research funding (not related to the current work) from Pfizer, MSD, and Gilead Sciences. COM has been a member of advisory boards for, received investigator-initiated grants from (not related to the current work), and given lectures for Gilead Sciences, Pfizer, MSD, and Orphan Australia. DCMK has sat on an advisory board for Pfizer and receives financial support (not related to the current work) from Pfizer, Roche, MSD, Novartis, and Gilead Sciences. All other authors: no conflict of interest. Preliminary data from this work were presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, USA, 2013, abstract M-1273.